Merck

July 16, 2019

FDA Will Review Application Seeking Expansion of Keytruda’s Dosing Schedule

News

The U.S. Food and Drug Administration (FDA) has accepted for review six supplemental biologics license applications (sBLAs) seeking to expand the dosing schedule of Keytruda (pembrolizumab) so the medication ... Read more

June 21, 2019

Bemcentinib-Keytruda Combo Provides Durable Response in Advanced NSCLC, Phase 2 Trial Shows

News

Combining bemcentinib with Keytruda (pembrolizumab) has shown efficacy and led to longer survival than previous second-line treatments in patients with advanced non-small cell lung cancer (NSCLC), according to updated ... Read more

June 12, 2019

FDA Approves Keytruda for Metastatic or Recurrent Head and Neck Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line therapy for patients with metastatic or recurrent and inoperable head and neck squamous cell carcinoma (HNSCC) ... Read more

June 11, 2019

Keytruda Improves Survival of Patients with Recurrent or Metastatic Head, Neck Cancer, Phase 3 Trial Shows

News

First-line treatment with Keytruda (pembrolizumab) in combination with chemotherapy prolongs the survival of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), compared to standard of care ... Read more

April 30, 2019

Keytruda-Inlyta Combo Approved by FDA for Untreated Advanced Kidney Cancer

News

The U.S. Food and Drug Administration (FDA) has approved a combination of Keytruda (pembrolizumab) plus Inlyta (axitinib) for the initial treatment of patients with advanced renal cell carcinoma, the ... Read more

March 27, 2019

Phase 2 Clinical Trial of CRS-207, Keytruda Combo for MPM is Discontinued

News

A combination of the immunotherapies Keytruda (pembrolizumab) and CRS-207 is safe, but has no evidence of clinical activity in adults with malignant pleural mesothelioma who failed prior lines of therapy, a ... Read more

March 20, 2019

EU Approves Keytruda/Chemo Combo to Treat Metastatic Squamous NSCLC

News

The European Commission has approved a combination of Keytruda (pembrolizumab) plus standard chemotherapy for the initial treatment of metastatic squamous non-small cell lung cancer (NSCLC), Merck (known as MSD ... Read more

March 13, 2019

Immune Checkpoint Inhibitors Safe, Effective in HIV-positive Patients with Advanced Cancer, Research Reveals

News

Immune checkpoint inhibitors may be safe and effective in advanced cancer patients with human immunodeficiency virus (HIV), according to a review study. The research, “Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in ... Read more

March 5, 2019

FDA Grants Priority Review to Keytruda for Advanced Small Cell Lung Cancer

News

The U.S. Food and Drug Administration has accepted Merck‘s application seeking accelerated approval of Keytruda (pembrolizumab) for the treatment of advanced small cell lung cancer (SCLC) patients who failed at least two prior ... Read more

February 27, 2019

FDA Approves Keytruda for Melanoma Patients After Tumor Resection

News

The U.S. Food and Drug Administration has approved the use of Keytruda (pembrolizumab) as a treatment for melanoma patients with stage 3 disease — cancer cells have spread to the ... Read more

Pin It on Pinterest